Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Fautrel

Showing results (101-110 of 370) with videos related to

Pageof 37
Sort By:
Rheumatology (Oxford, England)|January 12, 2017
Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patientsSandra Kossi, Sabrina Dadoun, Guillaume Geri, et al.
Rheumatology (Oxford, England)|January 24, 2012
Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literatureSuzanne M M Verstappen, Bruno Fautrel, Sabrina Dadoun, et al.
Joint Bone Spine|March 18, 2015
Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studiesStephanie Harvard, Laure Gossec, Thao Pham, et al.
Annals of the Rheumatic Diseases|September 24, 2024
Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's diseaseSara Bindoli, Arianna De Matteis, Stéphane Mitrovic, et al.
Cost Effectiveness and Resource Allocation : C/E|September 15, 2017
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimatesStephanie Harvard, Daphne Guh, Nick Bansback, et al.
Joint Bone Spine|November 10, 2016
Is the widely-used score in axial spondyloarthritis, Bath Ankylosing Spondylitis Disease Activity Index, influenced by patients' optimism? A cross-sectional study of 206 patientsStéphanie Fabre, Anna Molto, Sarah Kreis, et al.
Rheumatology (Oxford, England)|March 25, 2017
Dosing down with biologic therapies: a systematic review and clinicians' perspectiveChristopher J Edwards, Bruno Fautrel, Hendrik Schulze-Koops, et al.
Arthritis Care & Research|February 14, 2023
Influence of Sex on Early Axial Spondyloarthritis: A Six-Year Longitudinal Analysis From a Large National CohortKrystel Aouad, Anne Tournadre, Florian Lucasson, et al.
Annals of the Rheumatic Diseases|September 24, 2024
Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's diseaseArianna De Matteis, Sara Bindoli, Fabrizio De Benedetti, et al.
RMD Open|June 26, 2023
Serum calprotectin levels do not predict subsequent relapse in rheumatoid arthritis in remission: a post-hoc analysis of STRASS studyXavier Romand, Margot Clapasson, Minh Vu Chuong, et al.
Pageof 37

Showing results (101-110 of 370) with videos related to

Sort By:
Pageof 37
Rheumatology (Oxford, England)|January 12, 2017
Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patientsSandra Kossi, Sabrina Dadoun, Guillaume Geri, et al.
Rheumatology (Oxford, England)|January 24, 2012
Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literatureSuzanne M M Verstappen, Bruno Fautrel, Sabrina Dadoun, et al.
Joint Bone Spine|March 18, 2015
Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studiesStephanie Harvard, Laure Gossec, Thao Pham, et al.
Annals of the Rheumatic Diseases|September 24, 2024
Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's diseaseSara Bindoli, Arianna De Matteis, Stéphane Mitrovic, et al.
Cost Effectiveness and Resource Allocation : C/E|September 15, 2017
Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimatesStephanie Harvard, Daphne Guh, Nick Bansback, et al.
Joint Bone Spine|November 10, 2016
Is the widely-used score in axial spondyloarthritis, Bath Ankylosing Spondylitis Disease Activity Index, influenced by patients' optimism? A cross-sectional study of 206 patientsStéphanie Fabre, Anna Molto, Sarah Kreis, et al.
Rheumatology (Oxford, England)|March 25, 2017
Dosing down with biologic therapies: a systematic review and clinicians' perspectiveChristopher J Edwards, Bruno Fautrel, Hendrik Schulze-Koops, et al.
Arthritis Care & Research|February 14, 2023
Influence of Sex on Early Axial Spondyloarthritis: A Six-Year Longitudinal Analysis From a Large National CohortKrystel Aouad, Anne Tournadre, Florian Lucasson, et al.
Annals of the Rheumatic Diseases|September 24, 2024
Systemic juvenile idiopathic arthritis and adult-onset Still's disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still's diseaseArianna De Matteis, Sara Bindoli, Fabrizio De Benedetti, et al.
RMD Open|June 26, 2023
Serum calprotectin levels do not predict subsequent relapse in rheumatoid arthritis in remission: a post-hoc analysis of STRASS studyXavier Romand, Margot Clapasson, Minh Vu Chuong, et al.
Pageof 37